CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 23 enrolled
Drug / intervention
Stereotactic body radiosurgery +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01347333
NCT01347333N/ACompleted
CompareCT.gov

Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Liver Metastases and Primary Liver Tumors

Mercy Research·interventional·Posted May 4, 2011·Updated Mar 3, 2020

In Brief

A clinical study evaluating Stereotactic body radiosurgery and Stereotactic Body Radiotherapy for Liver Metastases and 2 related conditions. Completed, enrolled 23 participants across 1 site.

Detailed Summary

This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary liver tumors such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Metastases, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 4, 2011
Enrollment StartSep 1, 2008
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8 yearsPosted 15.2 years ago

Interventions

Stereotactic body radiosurgeryradiation

36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)

Stereotactic Body Radiotherapyradiation

26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)